Abstract
BackgroundTo investigate visual recovery after treatment of acute optic neuritis (ON) with either oral or intravenous high-dose methylprednisolone, in order to establish the best route of administration.MethodsRetrospective analysis of patients treated with oral or intravenous high-dose (≥500 mg per day) methylprednisolone for acute ON of unknown or demyelinating etiology. Twenty-eight patients were included in each treatment group. Visual acuity was measured with the Snellen letter chart, color vision with Boström-Kugelberg pseudo-isochromatic plates, and visual field with a Humphrey Field Analyzer.ResultsThe treatment results were similar in the two groups at follow-up, with no significant difference in visual acuity (p = 0.54), color vision (p = 0.18), visual field mean deviation (p = 0.39) or the number of highly significantly depressed test points (p = 0.46).ConclusionsThe results show no clinical disadvantage of using oral high-dose corticosteroids compared to intravenous administration in the treatment of acute ON, which would facilitate the clinical management of these patients.
Highlights
To investigate visual recovery after treatment of acute optic neuritis (ON) with either oral or intravenous high-dose methylprednisolone, in order to establish the best route of administration
Corticosteroids have been widely used for the treatment of multiple sclerosis (MS) relapse and optic neuritis, and the effect on short-term recovery of visual function has been well documented, while there are no long-term effects on visual outcome [3,4,5,6,7,8]
Visual acuity was measured with the Snellen letter chart (Ortho-KM, Lund, Sweden), color vision with Boström-Kugelberg pseudo-isochromatic plates (BK) (KIFA, Stockholm, Sweden) [12], and visual field with a Humphrey Field Analyzer (HFA), SITA Standard program 30–2 or 24–2 (Carl Zeiss Meditec, Dublin, Calif, USA)
Summary
To investigate visual recovery after treatment of acute optic neuritis (ON) with either oral or intravenous high-dose methylprednisolone, in order to establish the best route of administration. Methods: Retrospective analysis of patients treated with oral or intravenous high-dose (≥500 mg per day) methylprednisolone for acute ON of unknown or demyelinating etiology. Optic neuritis (ON) is an inflammatory disease of the optic nerve. It typically manifests as subacute visual loss with pain that is often exacerbated by eye movement. Corticosteroids have been widely used for the treatment of MS relapse and optic neuritis, and the effect on short-term recovery of visual function has been well documented, while there are no long-term effects on visual outcome [3,4,5,6,7,8]. The best dosage, length of treatment and route of administration have not yet been
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
